• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

成像技术的进展用于检测帕金森病的非运动前驱标志物并探索治疗转化机会。

Imaging advances to detect non-motor prodromal markers of Parkinson's disease and explore therapeutic translation opportunities.

作者信息

Palanivel Mathangi, Ghosh Krishna Kanta, Mallam Madhav, Bhuvanakantham Raghavan, Padmanabhan Parasuraman, Lim Kah-Leong, Gulyás Balázs

机构信息

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.

Cognitive Neuroimaging Centre, Nanyang Technological University, Singapore, Singapore.

出版信息

NPJ Parkinsons Dis. 2025 Jun 18;11(1):174. doi: 10.1038/s41531-025-01004-0.

DOI:10.1038/s41531-025-01004-0
PMID:40533452
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12177059/
Abstract

Parkinson's disease (PD) is a progressive neurological disorder marked by late-emerging motor symptoms, but early non-motor signs like hyposmia and REM sleep behavior disorder may precede diagnosis by years. Identifying non-motor biomarkers during this prodromal phase could predict phenoconversion and enable early interventions. This narrative review outlines key prodromal non-motor symptoms, summarizes imaging technologies for early detection, and explores their translational potential in guiding timely, neuroprotective therapies for at-risk individuals.

摘要

帕金森病（PD）是一种进行性神经疾病，其特征为出现较晚的运动症状，但嗅觉减退和快速眼动睡眠行为障碍等早期非运动症状可能在诊断前数年就已出现。在此前驱期识别非运动生物标志物可以预测表型转换并实现早期干预。这篇叙述性综述概述了关键的前驱期非运动症状，总结了早期检测的成像技术，并探讨了它们在指导为高危个体及时提供神经保护治疗方面的转化潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/0407537583f8/41531_2025_1004_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/8cdfccba2816/41531_2025_1004_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/4bb0a9e68b25/41531_2025_1004_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/9237edfb2c95/41531_2025_1004_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/bda03e05de77/41531_2025_1004_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/c39eb8d65481/41531_2025_1004_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/8a5c6d48bce0/41531_2025_1004_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/851d1a3823fa/41531_2025_1004_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/a118af22edcf/41531_2025_1004_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/8da17d8ed563/41531_2025_1004_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/116f9e335b25/41531_2025_1004_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/237ffce149fa/41531_2025_1004_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/1608df488365/41531_2025_1004_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/cd5dd50d066d/41531_2025_1004_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/0407537583f8/41531_2025_1004_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/8cdfccba2816/41531_2025_1004_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/4bb0a9e68b25/41531_2025_1004_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/9237edfb2c95/41531_2025_1004_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/bda03e05de77/41531_2025_1004_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/c39eb8d65481/41531_2025_1004_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/8a5c6d48bce0/41531_2025_1004_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/851d1a3823fa/41531_2025_1004_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/a118af22edcf/41531_2025_1004_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/8da17d8ed563/41531_2025_1004_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/116f9e335b25/41531_2025_1004_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/237ffce149fa/41531_2025_1004_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/1608df488365/41531_2025_1004_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/cd5dd50d066d/41531_2025_1004_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5420/12177059/0407537583f8/41531_2025_1004_Fig14_HTML.jpg

相似文献

1
Imaging advances to detect non-motor prodromal markers of Parkinson's disease and explore therapeutic translation opportunities.成像技术的进展用于检测帕金森病的非运动前驱标志物并探索治疗转化机会。
NPJ Parkinsons Dis. 2025 Jun 18;11(1):174. doi: 10.1038/s41531-025-01004-0.
2
Using prodromal non-motor symptoms to predict Parkinson's disease onset and motor phenotype.利用前驱期非运动症状预测帕金森病的发病及运动表型。
J Neurol Neurosurg Psychiatry. 2025 Jun 19. doi: 10.1136/jnnp-2024-335429.
3
Distinct brain atrophy progression subtypes underlie phenoconversion in isolated REM sleep behaviour disorder.不同的脑萎缩进展亚型是孤立性快速眼动睡眠行为障碍中表型转换的基础。
EBioMedicine. 2025 May 29;117:105753. doi: 10.1016/j.ebiom.2025.105753.
4
Characterizing Parkinson's Disease Clinical and Biomarker Interactions in REM Sleep Behavior Disorder.在快速眼动睡眠行为障碍中表征帕金森病的临床与生物标志物相互作用
medRxiv. 2025 May 18:2025.05.16.25327469. doi: 10.1101/2025.05.16.25327469.
5
Use of β-adrenoreceptor drugs and Parkinson's disease incidence in women from the French E3N cohort study.来自法国E3N队列研究的女性中β-肾上腺素能受体药物的使用与帕金森病发病率
J Parkinsons Dis. 2025 Apr 29:1877718X251330993. doi: 10.1177/1877718X251330993.
6
Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single-center open-label clinical phase I trial (NEON trial).静脉注射脂质体GM1治疗帕金森病患者的安全性和耐受性：一项单中心开放标签的I期临床试验（NEON试验）。
PLoS Med. 2025 May 13;22(5):e1004472. doi: 10.1371/journal.pmed.1004472. eCollection 2025 May.
7
Enhancing the diagnostic potential of electroretinography in Parkinson's disease: A review of protocol and cohort criteria.提高视网膜电图在帕金森病中的诊断潜力：方案与队列标准综述
J Parkinsons Dis. 2025 Jun;15(4):694-709. doi: 10.1177/1877718X251331863. Epub 2025 Apr 29.
8
Intestinal biomarkers, microbiota composition, and genetic predisposition to inflammatory bowel disease as predictors of Parkinson's disease manifestation.肠道生物标志物、微生物群组成以及炎症性肠病的遗传易感性作为帕金森病表现的预测指标。
J Parkinsons Dis. 2025 May 7:1877718X251328567. doi: 10.1177/1877718X251328567.
9
Incidence of antiepileptic drug use in Parkinson's disease.帕金森病中抗癫痫药物的使用发生率。
J Parkinsons Dis. 2025 Jun;15(4):780-788. doi: 10.1177/1877718X251343079. Epub 2025 May 23.
10
Dementia risk prediction in early Parkinson's disease: Validation and genetic integration of the Montreal Parkinson risk of dementia scale (MoPaRDS).早期帕金森病的痴呆风险预测：蒙特利尔帕金森痴呆风险量表（MoPaRDS）的验证与基因整合
J Parkinsons Dis. 2025 Apr 29:1877718X251329857. doi: 10.1177/1877718X251329857.

本文引用的文献

1
Noninvasive Diagnostic Method to Objectively Measure Olfaction and Diagnose Smell Disorders by a Molecularly Targeted Fluorescence Imaging Agent.一种通过分子靶向荧光成像剂客观测量嗅觉并诊断嗅觉障碍的非侵入性诊断方法。
J Nucl Med. 2024 Aug 1;65(8):1293-1300. doi: 10.2967/jnumed.123.266123.
2
Dopamine Synthesis in the Nigrostriatal Dopaminergic System in Patients at Risk of Developing Parkinson's Disease at the Prodromal Stage.前驱期帕金森病风险患者黑质纹状体多巴胺能系统中的多巴胺合成
J Clin Med. 2024 Feb 2;13(3):875. doi: 10.3390/jcm13030875.
3
Changes in cerebral cortex activity during a simple motor task after MRgFUS treatment in patients affected by essential tremor and Parkinson's disease: a pilot study using functional NIRS.
磁共振引导聚焦超声治疗后震颤和帕金森病患者简单运动任务时大脑皮层活动的变化：使用功能近红外光谱的初步研究。
Phys Med Biol. 2024 Jan 11;69(2). doi: 10.1088/1361-6560/ad164e.
4
Neuroimaging and serum biomarkers of neurodegeneration and neuroplasticity in Parkinson's disease patients treated by intermittent theta-burst stimulation over the bilateral primary motor area: a randomized, double-blind, sham-controlled, crossover trial study.对双侧初级运动区进行间歇性θ波爆发刺激治疗的帕金森病患者神经退行性变和神经可塑性的神经影像学及血清生物标志物：一项随机、双盲、假对照、交叉试验研究。
Front Aging Neurosci. 2023 Oct 5;15:1258315. doi: 10.3389/fnagi.2023.1258315. eCollection 2023.
5
Early detection of Parkinson's disease: Systematic analysis of the influence of the eyes on quantitative biomarkers in resting state electroencephalography.帕金森病的早期检测：关于眼睛对静息态脑电图定量生物标志物影响的系统分析
Heliyon. 2023 Oct 4;9(10):e20625. doi: 10.1016/j.heliyon.2023.e20625. eCollection 2023 Oct.
6
Retinal Optical Coherence Tomography Features Associated With Incident and Prevalent Parkinson Disease.与新发和现患帕金森病相关的视网膜光学相干断层扫描特征。
Neurology. 2023 Oct 17;101(16):e1581-e1593. doi: 10.1212/WNL.0000000000207727. Epub 2023 Aug 21.
7
Cortical excitability in patients with REM sleep behavior disorder with abnormal TRODAT-1 SPECT scan: an insight into prodromal Parkinson's disease.快速眼动睡眠行为障碍患者且TRODAT-1单光子发射计算机断层扫描异常时的皮质兴奋性：对帕金森病前驱期的见解
Front Neurol. 2023 May 24;14:1156041. doi: 10.3389/fneur.2023.1156041. eCollection 2023.
8
Magnetoencephalography to measure the effect of contact point-specific deep brain stimulation in Parkinson's disease: A proof of concept study.应用脑磁图测量帕金森病接触点特异性深部脑刺激的效果：一项概念验证研究。
Neuroimage Clin. 2023;38:103431. doi: 10.1016/j.nicl.2023.103431. Epub 2023 May 10.
9
Uncovering the Correlation between COVID-19 and Neurodegenerative Processes: Toward a New Approach Based on EEG Entropic Analysis.揭示新冠病毒与神经退行性过程之间的关联：迈向基于脑电图熵分析的新方法。
Bioengineering (Basel). 2023 Mar 29;10(4):435. doi: 10.3390/bioengineering10040435.
10
Neuromapping olfactory stimulation using magnetoencephalography - visualizing smell, a proof-of-concept study.使用脑磁图进行嗅觉刺激的神经图谱绘制——嗅觉可视化，一项概念验证研究。
Front Allergy. 2023 Jan 9;3:1019265. doi: 10.3389/falgy.2022.1019265. eCollection 2022.